Member Info for Laura2022

Nice buy

Eg

Can sell 15mln above 0.8p

Goup

Let's see over next few weeks now overhang cleared

Other than parallels with Bell and not squeaky conduct in Africa

Eg the fake lithium

Relevant to the basket case RRR how .?

Thanks Trench

These conferences are certainly working last 12mths with amount of new and repeat business

Good post OSD

oldsharedog

Posted in: NFX

Posts: 2,922

Price: 0.09

No Opinion

RE: Grok says18 Jul 2025 18:21

Trombone, although I agree with your sentiment I very much doubt that NFX haven’t mapped out a plan, which I believe will move forward very soon.

I believe that NFX will be one of the most successful stocks this year - let’s hope so 🤞

From 29th May

application for US FDA orphan drug designation and continue discussions with potential future licensing partners and will provide further updates in due course as appropriate."

0.78 -0.8p

But no/little stock at 0.8p

Overhang cleared

Jvip

Looks like NFX going to pop

Could be $10,000 it hasn't and won't have ANY positive effect on RRR which has lost 90% every year for over 5yrs

See yesterday helpful

C10mln

Bid rising and very little now at 0.8p

Above 0.8p bid now

Moving nicely today

Same overhang clearing NFX too

Bought another 2.5mln at 0.791p

Hopefully shows this time !!

Ask dropped but bid rising

Added some yesterday but did not show??? 2.6mln shares

Will add today , tight spread and bid slightly increasing to 0.757p and ask 8.08

Think the overhang is nearly gone

IP granted in all major jurisdictions, EMA approval given in May. FDA is the final one, company is in preclinical deal mode.

"Our valuation of NXP002 as a preclinical asset using a 13% WACC gives a risk adjusted valuation of NFX of £52.8m.The de-risked global value of NXP002 in IPF is £528m, which illustrates its total value potential. NFX is looking to license the asset before Phase I, in which case we would anticipate a global deal value of between $360-450m, in up front and milestone payments, plus single digit royalties on sales, increasing in value in proportion to the stage of development of the underlying asset: from feasibility up to the full Phase I."

They've completely re ramped their website which last year was just a simple format

Very good now

https://www.beyondblood.co/technology